| Yang, Tao |
NCT05461820: Effects of Different Treatment Schemes on the Regulation and Recurrence of Graves' Disease |
|
|
| Recruiting | 4 | 240 | RoW | Methimazole, Thyrozol | The First Affiliated Hospital with Nanjing Medical University | Graves Disease, Relapse, Treatment, Drug Withdrawal | 12/23 | 07/30 | | |
| Completed | 3 | 533 | RoW | Chiglitazar 32mg, Bilessglu, CS038, Chiglitazar 48mg, Placebo, Chiglitazar simulator, Metformin Hydrochloride, Glucophage | Chipscreen Biosciences, Ltd. | Type 2 Diabetes | 02/23 | 02/23 | | |
NCT05745259: Thrombolysis Treated With TNK-tPA in Acute Ischemic Stroke Patients （3T Stroke-Ⅲ） |
|
|
| Recruiting | 3 | 1630 | RoW | Alteplase, rt-PA, Tenecteplase, TNK-tPA | Beijing Tiantan Hospital, Jiangsu FENG HUA Biotech Pharmaceutical Co., Ltd, The Place Pharmaceutical(Jiangsu) Co., Ltd | Acute Ischemic Stroke | 11/23 | 03/24 | | |
NCT05352516 / 2022-002188-31: A Study to Evaluate the Efficacy and Safety of HLX14 vs. Denosumab Prolia® in Postmenopausal Women With Osteoporosis at High Risk of Fracture |
|
|
| Completed | 3 | 514 | RoW | HLX14, Prolia® | Shanghai Henlius Biotech, Shanghai Henlius Biotech, Inc. | Postmenopausal | 12/23 | 07/24 | | |
| Recruiting | 3 | 2100 | Europe, Canada, Japan, US, RoW | Rimegepant/BHV3000, Matching placebo | Pfizer | Pediatric Migraine | 01/29 | 01/29 | | |
NCT06511895: AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27) |
|
|
| Recruiting | 2 | 150 | RoW | AZD4205 | Dizal Pharmaceuticals | Peripheral T Cell Lymphoma | 05/25 | 12/26 | | |
NCT05985863: Human Umbilical Cord Mesenchymal Stem Cell Transplantation for The Treatment of Acute-on-Chronic Liver Failure |
|
|
| Recruiting | 1/2 | 150 | RoW | standard medical treatment, Placebo, hUC-MSC, hUC-MSC_Prolonged | Beijing 302 Hospital, Shulan (Hang Zhou) Hospital, BeijingYouan Hospital, Shenzhen Third People's Hospital, Shen Zhen Wingor Biotechnology CO. LTD | Acute-On-Chronic Liver Failure | 12/26 | 12/28 | | |
| Recruiting | 1 | 100 | RoW | HMPL-760 | Hutchison Medipharma Limited | B-Cell Non-Hodgkin's Lymphoma | 07/24 | 04/26 | | |
NCT04691076: Effect of Low-dose Esketamine Combined With Target-controlled Infusion of Propofol for Painless Gastrointestinal Endoscopy |
|
|
| Recruiting | N/A | 1000 | RoW | Propofol, Esketamine, Fentanyl | Tianjin Union Medical Center | Pain, Anesthesia | 12/21 | 02/22 | | |
NCT05784506: Metabolites Profiling Reveals Nutrient Processing Patterns Upon Dietary Loading |
|
|
| Not yet recruiting | N/A | 150 | RoW | Macronutrients, Mixed meal tolerance test (MMTT) | Nanjing Medical University | Metabolism Disorder, Nutrition | 07/23 | 12/23 | | |
NCT05999656: Human Cord Blood Mononuclear Cells in the Treatment of Refractory Diabetic Foot |
|
|
| Recruiting | N/A | 24 | RoW | human cord blood-derived mononuclear cells (HCB-MNCs) | The First Affiliated Hospital with Nanjing Medical University, Shandong Qilu Stem Cells Engineering Co., Ltd. | Refractory Diabetic Foot, Human Cord Blood-derived Mononuclear Cells, Efficacy, Safety, Local Injection | 05/24 | 11/24 | | |
NCT06273631: Effect of Changes in Carbohydrate Intake Patterns on Glucose Control in Patients with Type 1 Diabetes |
|
|
| Recruiting | N/A | 80 | RoW | diverse carbohydrate diet, middle carbohydrate diet | Yang Tao | Type 1 Diabetes, Diet Intervention, Glucose Control | 12/25 | 12/26 | | |
NCT05498974: China Diabetes Type 1 Study (CD1S) by China Alliance for Type 1 Diabetes |
|
|
| Recruiting | N/A | 20000 | RoW | Standard type 1 diabetes management model constructed by China Alliance for Type 1 Diabetes in each center | Second Xiangya Hospital of Central South University | Type1diabetes, Diabetes | 12/35 | 12/35 | | |
